Incretin-based weight-loss interventions showed muscle-related losses exceeding benchmarks in two-thirds of cases.
The systematic review analyzed 36 randomized controlled trials, focusing on therapies like liraglutide and semaglutide.
Among studies with evaluable muscle indices, 68% exceeded muscle-loss benchmarks, indicating significant muscle loss.
Findings suggest muscle loss is not unique to incretin therapies but may reflect broader physiological responses to weight loss.
The review highlights the need for objective physical function outcomes and better representation of older populations in future trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
